Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lectin-like oxidized low-density lipoprotein receptor 1 attenuates pneumonia-induced lung injury
Filiz T. Korkmaz, … , Katrina E. Traber, Lee J. Quinton
Filiz T. Korkmaz, … , Katrina E. Traber, Lee J. Quinton
Published October 20, 2022
Citation Information: JCI Insight. 2022;7(23):e149955. https://doi.org/10.1172/jci.insight.149955.
View: Text | PDF
Research Article Immunology Inflammation

Lectin-like oxidized low-density lipoprotein receptor 1 attenuates pneumonia-induced lung injury

  • Text
  • PDF
Abstract

Identifying host factors that contribute to pneumonia incidence and severity are of utmost importance to guiding the development of more effective therapies. Lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1, encoded by OLR1) is a scavenger receptor known to promote vascular injury and inflammation, but whether and how LOX-1 functions in the lung are unknown. Here, we provide evidence of substantial accumulation of LOX-1 in the lungs of patients with acute respiratory distress syndrome and in mice with pneumonia. Unlike previously described injurious contributions of LOX-1, we found that LOX-1 is uniquely protective in the pulmonary airspaces, limiting proteinaceous edema and inflammation. We also identified alveolar macrophages and recruited neutrophils as 2 prominent sites of LOX-1 expression in the lungs, whereby macrophages are capable of further induction during pneumonia and neutrophils exhibit a rapid, but heterogenous, elevation of LOX-1 in the infected lung. Blockade of LOX-1 led to dysregulated immune signaling in alveolar macrophages, marked by alterations in activation markers and a concomitant elevation of inflammatory gene networks. However, bone marrow chimeras also suggested a prominent role for neutrophils in LOX-1–mediated lung protection, further supported by LOX-1+ neutrophils exhibiting transcriptional changes consistent with reparative processes. Taken together, this work establishes LOX-1 as a tissue-protective factor in the lungs during pneumonia, possibly mediated by its influence on immune signaling in alveolar macrophages and LOX-1+ airspace neutrophils.

Authors

Filiz T. Korkmaz, Anukul T. Shenoy, Elise M. Symer, Lillia A. Baird, Christine V. Odom, Emad I. Arafa, Ernest L. Dimbo, Elim Na, William Molina-Arocho, Matthew Brudner, Theodore J. Standiford, Jawahar L. Mehta, Tatsuya Sawamura, Matthew R. Jones, Joseph P. Mizgerd, Katrina E. Traber, Lee J. Quinton

×

Figure 6

Alveolar macrophages exhibit a dysregulated phenotype with LOX-1 inhibition.

Options: View larger image (or click on image) Download as PowerPoint
Alveolar macrophages exhibit a dysregulated phenotype with LOX-1 inhibit...
(A) Age-matched C57BL/6 mice were intratracheally treated with 10 μg anti–LOX-1 IgG or control IgG and E. coli for 6–36 hours (n = 6–8 per group). FACS-sorted alveolar macrophages were subsequently analyzed by flow cytometry for (B) levels of reactive oxygen species (ROS) at 6 hours, (C) IL-6 and CXCL2 expression at 24 hours, or (D) CD206 expression at 18 hours after anti–LOX-1 or IgG treatment and infection. Intracellular flow cytometry was performed on fixed cells at 18–36 hours after anti–LOX-1 or control IgG treatment and E. coli infection to determine (E) Arginase 1, iNOS, MHCII, and CD11b expression (MFI) and (F) total alveolar macrophage numbers. Data are represented as mean ± SEM with individual data points representative of mice from 2–3 independent experiments. Statistical analysis was performed on normalized (log-transformed) IL-6 and CXCL2 gene expression (fold change). ***P < 0.001, *P < 0.05 for 1-way ANOVA with Holm-Šídák post hoc test (B); 2-tailed Welch’s t test (C); 2-tailed, unpaired t test (D); or 2-way ANOVA with Holm-Šídák post hoc test (D and E).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts